 |
JOURNAL TOOLS |
| eTOC |
| To subscribe |
| Submit an article |
| Recommend to your librarian |
ARTICLE TOOLS |
| Reprints |
| Permissions |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
CLINICAL CASES
Giornale Italiano di Dermatologia e Venereologia 2004 April;139(2):139-43
Copyright © 2004 EDIZIONI MINERVA MEDICA
language: English, Italian
Pemphigus vulgaris and rituximab. Report of a case
Marzocchi V. 1, Virgolini L. 2
1 Unit of Dermatology “S. Maria della Misericordia” Hospital, Udine, Italy 2 Medicine Unit II, Department of Medicine I “S. Maria degli Angeli” Hospital, Pordenone, Italy
Pemphigus vulgaris is a serious bullous disease of auto-immune pathogenesis affecting the skin and mucous membranes, caused by the presence of desmosomal anti-cadherin antibodies. The disease is potentially fatal, and is generally treated with immuno-suppressors, usually corticosteroids. This paper describes a case of pemphigus vulgaris which, resistant to all other kinds of therapy, succumbed to rituximab, an anti-CD20 B-cell murine antibody, made suitable for use on humans.